High Incidence of False-Positive Results in Patients with Acute Infections Other than COVID-19 by the Liaison SARS-CoV-2 Commercial Chemiluminescent Microparticle Immunoassay for Detection of IgG Anti-SARS-CoV-2 Antibodies

摘要

Coronavirus disease 19 (COVID-19), caused by severe acute respiratory syndrome coro-navirus2(SARS-CoV-2),isamajorpandemic(1).DiagnosisisbasedondetectionofviralRNA, whereas the immune response to SARS-CoV-2 is measured by serological tests whichdetect antibodies (Abs) directed against nucleocapsid and/or spike envelope proteins ofthe virus. The median day of IgG seroconversion is around 14days after symptom onset (2),but a high interindividual variation has been reported, as well as contrasting performancesbetween commercial assays (3–6).